Evidence map›Paper›PMID 29128754›Full record

ArticleVirology2018

Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.

Ahmed Atef Mesalam, Isabelle Desombere, Ali Farhoudi, Freya Van Houtte, Lieven Verhoye, Jonathan Ball, Jean Dubuisson, Steven K H Foung, Arvind H Patel, Mats A A Persson and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 6 countries.

Ahmed Atef MesalamDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium; Therapeutic Chemistry Department, National Research Centre (NRC), Dokki, Cairo, Egypt. Electronic address: Ahmed.Mesalam@ugent.be.
Isabelle DesombereDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium. Electronic address: Isabelle.Desombere@wiv-isp.be.
Ali FarhoudiDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium. Electronic address: Ali.Farhoudi@ugent.be.
Freya Van HoutteDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium. Electronic address: Freya.VanHoutte@ugent.be.
Lieven VerhoyeDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium. Electronic address: Lieven.Verhoye@ugent.be.
Jonathan BallSchool of Life Sciences, The University of Nottingham, Nottingham NG7 2RD, UK; Nottingham Digestive Diseases Centre, National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and The University of Nottingham, Nottingham NG7 2UH, UK. Electronic address: Jonathan.Ball@nottingham.ac.uk.
Jean DubuissonUniv. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection & Immunity of Lille, F-59000 Lille, France. Electronic address: Jean.Dubuisson@ibl.cnrs.fr.
Steven K H FoungDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: sfoung@stanford.edu.
Arvind H PatelMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK. Electronic address: Arvind.Patel@glasgow.ac.uk.
Mats A A PerssonKarolinska Institutet, Department of Clinical Neurosciences, Center for Molecular Medicine, Karolinska University Hospital Solna, 171 76 Stockholm, Sweden. Electronic address: Mats.Persson@ki.se.
Geert Leroux-RoelsDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium. Electronic address: Geert.LerouxRoels@ugent.be.
Philip MeulemanDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium. Electronic address: Philip.Meuleman@ugent.be.
Ghent University · BEGhent University Hospital · BECentre National de la Recherche Scientifique · FRKarolinska University Hospital · SEMRC University of Glasgow Centre for Virus Research · GBNottingham University Hospitals NHS Trust · GBStanford Medicine · USUniversity College Ghent · BE

Funding

Structure-Based Vaccine Design for Hepatits C VirusR01AI132213 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI ANDRIANOV, ALEXANDER, FOUNG, STEVEN · 2017 to 2021
$6.0M
Project 2 - FranceU19AI123862 · NIAID · STANFORD UNIVERSITY · PI FOUNG, STEVEN · 2016 to 2020
$3.9M
Structure-based HCV vaccine designR21AI126582 · NIAID · STANFORD UNIVERSITY · PI FOUNG, STEVEN, MARIUZZA, ROY A · 2016 to 2017
$440k
Medical Research Council G0801169Medical Research Council MC_UU_12014/2Medical Research Council MC_UU12014/2NIAID NIH HHS R01 AI132213NIAID NIH HHS R21 AI126582NIAID NIH HHS U19 AI123862
6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) targeting the hepatitis C virus (HCV) envelope have been raised mainly against envelope protein 2 (E2), while the antigenic epitopes of envelope protein 1 (E1) are not fully identified. Here we describe the detailed characterization of a human mAb, designated A6, generated from an HCV genotype 1b infected patient. ELISA results showed reactivity of mAb A6 to full-length HCV E1E2 of genotypes 1a, 1b and 2a. Epitope mapping identified a region spanning amino acids 230-239 within the N-terminal region of E1 as critical for binding. Antibody binding to this epitope was not conformation dependent. Neutralization assays showed that mAb A6 lacks neutralizing capacity and does not interfere with the activity of known neutralizing antibodies. In summary, mAb A6 is an important tool to study the structure and function of E1 within the viral envelope, a crucial step in the development of an effective prophylactic HCV vaccine.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingEpitope MappingGenotypeHepacivirusHepatitis CHumansViral Envelope ProteinsAntibodies, MonoclonalAntibodies, NeutralizingE1 protein, Hepatitis C virusViral Envelope ProteinsAntibodyEntryEnvelope proteinHepatitis C virusVaccine

Identifiers

PMID29128754
PMCPMC5784761
OpenAlexW2767967441

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.